Sanders Morris Harris LLC cut its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 36.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 10,250 shares of the biotechnology company’s stock after selling 5,950 shares during the quarter. Sanders Morris Harris LLC’s holdings in Iovance Biotherapeutics were worth $76,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of IOVA. Barclays PLC boosted its stake in Iovance Biotherapeutics by 118.8% during the third quarter. Barclays PLC now owns 604,584 shares of the biotechnology company’s stock valued at $5,677,000 after buying an additional 328,284 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Iovance Biotherapeutics by 59.0% during the 3rd quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock valued at $37,872,000 after purchasing an additional 1,496,941 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Iovance Biotherapeutics in the 3rd quarter worth approximately $920,000. State Street Corp raised its holdings in shares of Iovance Biotherapeutics by 4.6% in the 3rd quarter. State Street Corp now owns 13,201,978 shares of the biotechnology company’s stock worth $123,967,000 after purchasing an additional 576,801 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in Iovance Biotherapeutics during the second quarter valued at approximately $12,929,000. Institutional investors own 77.03% of the company’s stock.
Iovance Biotherapeutics Trading Down 1.5 %
NASDAQ:IOVA traded down $0.09 during trading hours on Thursday, hitting $5.82. 607,346 shares of the stock traded hands, compared to its average volume of 9,701,952. The firm has a 50 day moving average price of $8.17 and a 200 day moving average price of $9.17. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -3.91 and a beta of 0.57. Iovance Biotherapeutics, Inc. has a fifty-two week low of $5.77 and a fifty-two week high of $18.33.
Insider Buying and Selling
In other Iovance Biotherapeutics news, Director Ryan D. Maynard sold 50,000 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total value of $503,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at $75,450. This represents a 86.96 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.10% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
IOVA has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. UBS Group began coverage on Iovance Biotherapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $17.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.00.
Read Our Latest Analysis on Iovance Biotherapeutics
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.
See Also
- Five stocks we like better than Iovance Biotherapeutics
- What is the Hang Seng index?
- 3 Cheap Small-Cap Banks for Dividend Growth Investors
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- Using the MarketBeat Stock Split Calculator
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report).
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.